Related Experiment Videos
Ravuconazole Eisai/Bristol-Myers Squibb
1Department of Microbiology and Clinical Microbiology, Hacettepe University Medical School, Ankara, Turkey. sarikan@metu.edu.tr
Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2002
Summary
Ravuconazole, a novel triazole antifungal, shows broad-spectrum activity against resistant fungal strains like Candida krusei and Cryptococcus neoformans. This compound is being developed for potential fungal infection treatment.
Area of Science:
- Pharmacology
- Mycology
Background:
- Eisai and Bristol-Myers Squibb (BMS) are developing ravuconazole, a triazole antifungal agent.
- Ravuconazole was selected for development due to its favorable safety profile and balanced antifungal activity.
- The compound demonstrated a broader antifungal spectrum compared to existing treatments like fluconazole and itraconazole.
Purpose of the Study:
- To evaluate the potential of ravuconazole as a treatment for fungal infections.
- To assess the antifungal spectrum of ravuconazole, particularly against resistant strains.
Main Methods:
- Preclinical and clinical development of ravuconazole.
- Comparative analysis of antifungal spectrum against fluconazole and itraconazole.
Main Results:
- Ravuconazole exhibits enhanced activity against Candida krusei and Cryptococcus neoformans strains.
- The compound possesses a broader antifungal spectrum than fluconazole and itraconazole.
Conclusions:
- Ravuconazole represents a promising candidate for treating fungal infections, especially those caused by resistant pathogens.
- Further clinical development (Phase II trials) is underway to establish its efficacy and safety.
- BMS sought a co-development partner for ravuconazole, indicating significant commercial interest.